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FNDC5/irisin has been recently postulated as beneficial in the treatment of obesity and diabetes because it is induced in muscle by
exercise, increasing energy expenditure. However, recent reports have shown thatWAT also secretes irisin and that circulating irisin
is elevated in obese subjects. The aim of this study was to evaluate irisin levels in conditions of extreme BMI and its correlation
with basal metabolism and daily activity. The study involved 145 female patients, including 96 with extreme BMIs (30 anorexic
(AN) and 66 obese (OB)) and 49 healthy normal weight (NW). The plasma irisin levels were significantly elevated in the OB
patients compared with the AN and NW patients. Irisin also correlated positively with body weight, BMI, and fat mass. The OB
patients exhibited the highest REE and higher daily physical activity compared with the AN patients but lower activity compared
with the NW patients. The irisin levels were inversely correlated with daily physical activity and directly correlated with REE. Fat
mass contributed to most of the variability of the irisin plasma levels independently of the other studied parameters.Conclusion.
Irisin levels are influenced by energy expenditure independently of daily physical activity but fat mass is the main contributing
factor.
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1. Introduction
A balance between energy intake and energy expenditure
is responsible for body weight maintenance; disturbances
in this balance may cause individuals to be underweight,
anorexic, overweight, or obese [1, 2]. Signals secreted by
peripheral tissues, such as fat or the digestive tract, are
active participants in body weight regulation by acting at
central level [3]. Skeletal muscle has recently been shown
to function as a peripheral endocrine organ by releasing
peptide signal molecules known as myokines, which are
implicated in the regulation of several physiological and
metabolic pathways [4, 5]. Myokines secreted during muscle
contraction may exert a protective role against illnesses
associated with sedentary lifestyles [6]. The muscle-secreted
peptide irisin has been recently described as a cleavage
product of the type I membrane protein fibronectin type
III domain containing 5 (FNDC5) [7]. In muscle, FNDC5
is induced by the peroxisome proliferator-activated receptor
𝛾 (PPAR𝛾) transcriptional coactivator PGC1-𝛼, which is
described as an essential mediator in the exercise-induced
energy expenditure cascade and stimulates several ben-
eficial effects of exercise in muscle tissue [7, 8]. After
physical activity, FNDC5 has been reported to promote
white adipose tissue browning by increasing thermogene-
sis and energy expenditure. Thus, augmentation of circu-
lating irisin levels by forced liver expression of FNDC5
using adenoviral vectors improves glucose tolerance and
reduces obesity of mice fed on a high-fat diet [7]. Under
this context, irisin was rapidly postulated to be bene-
ficial in the treatment of obesity, diabetes, and a wide
range of pathological conditions characterized by a vari-
able imbalance of energy demand and expenditure [4, 9–
13].
Unexpectedly, some studies have indicated that the cir-
culating irisin levels in humans correlate positively with
parameters of adiposity such as BMI and are the highest
in obese individuals [14–17]. On the other hand, a recent
paper reports that irisin correlates negatively with BMI,
waist-hip ratio, and fat mass in men and that circulat-
ing irisin is lower in nondiabetic overweight and obese
men [18, 19]. Our group has established a new perspec-
tive for FNDC5 by describing that FNDC5/irisin is also
an adipokine expressed and secreted by adipocytes from
white adipose tissue (WAT) in rats and humans [16]. We
have observed that short-term endurance exercise increases
FNDC5/irisin secretion by adipose tissue, while food restric-
tion decreased secretion. Accordingly, anorectic animals
showed discrete secretion of FNDC5/irisin, while fat from
obese animals oversecretes FNDC5/irisin. Thus, we pos-
tulated that adipose tissue may contribute to circulating
FNDC5/irisin and that the contribution may vary depend-
ing on the physiological state or the pathological situa-
tion.
The objective of this study was to evaluate the
circulating levels of irisin in conditions of extreme
BMI, such as anorexia and obesity, and the correlations
of irisin with basal metabolism and daily activ-
ity.
2. Materials and Methods
2.1. Subjects. A total of 145 females participated in this
study after being informed about the research and signing
informed consent. Thirty patients were anorexic (AN; BMI
17.3 ± 1.8 kg/m2; 28.1 ± 9.4 years), 66 were obese (OB; BMI
42.8 ± 6.7 kg/m2; 29.0 ± 6.2 years; 21.2% with type 2 diabetes
mellitus), and 49 were healthy, normal-weight controls (NW;
BMI 21.7 ± 1.6 kg/m2; 44.5 ± 11.4 years).
Enrolment into the study occurred between January
2010 and December 2012. All consecutive patients were
referred to seven centers from six Spanish sites (all involved
in the CIBERobn Spanish Research Network): the Eat-
ing Disorders Unit (Department of Psychiatry, Univer-
sity Hospital of Bellvitge-IDIBELL, Barcelona), the Depart-
ment of Endocrinology at the University Hospital of San-
tiago (Santiago de Compostela), the Department of Dia-
betes, Endocrinology and Nutrition (Clinic University Hos-
pital Virgen de Victoria, Ma´laga), the Department of
Endocrinology (University of Navarra, Pamplona), the Dia-
betes, Endocrinology andNutrition Department, Biomedical
Research Institute of Girona (IdIBGi-Doctor Josep Trueta
Hospital, Girona), the Hospital del Mar Research Institute
(IMIM-Hospital del Mar, Barcelona), and the Department
of Basic Psychology, Clinic and Psychobiology (University
Jaume I, Castello´n).
The AN patients were diagnosed by experienced clin-
icians (according to DSM-IV-TR diagnostic criteria) [20]
using the structured clinical interview for DSM IV Axis I
disorders (SCID-I) [21]. These AN patients at extreme BMI
were hospitalized, hence showing weaken health and very
limited physical activity.
The interviewers were trained for the administration
of these instruments. The following exclusion criteria were
applied to the clinical cases groups (AN and obese patients):
(1) male; (2) age under 18 or over 60 years, and (3) a comorbid
binge eating disorder in the obese patients (according to
DSM-IV-TR criteria, using SCID-I) [22]. Healthy controls
were recruited by several methods including word-of-mouth
recruitment and advertisements in the local university. Prior
to assessment, the healthy controls were asked about lifetime
or current presence of an endocrine disease or obesity. The
lifetime history of health or mental illnesses profile was
based on the general health questionnaire (GHQ)-28 [23].
The following exclusion criteria were applied to the healthy
control groups (NW): (1) individuals who have suffered a
lifetime eating disorder (assessed using SCID-I), (2) age
under 18 and over 60 years, (3) lifetime obesity (BMI > 30),
and (4) being male.
The procedures were approved by the ethical committees
of each of the aforementioned institutions.
2.2. Anthropometric, Body Composition, and Resting Energy
Expenditure Measurements. Anthropometric, body compo-
sition, and resting energy expenditure (REE) measure-
ments were performed by bioelectrical impedance (TANITA
MC-180 Multifrequency; TANITA Corporation of America,
Inc, Arlington Heights, IL, USA), equipped with 8 tactile
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electrodes with a platform with 2 electrodes for each foot
and 2 handgrips with 2 electrodes each. The bioelectrical
impedance analysis was chosen since it is able to predict the
REE without bias with respect to more costly equipment and
invasive procedures needed to directly measure REE [24].
2.3. Activity Variable. Physical activity was evaluated with
the Actiwatch AW7 (Actiwatch AW7; CamNtech Ltd., Cam-
bridge Neurotechnology, Cambridge, UK), which is a small
(39 × 32 × 9) and light-weight (10.5 g) accelerometer that
measures sleep-wake physical activity.The Actiwatch is worn
on the nondominant wrist for 6 days (4 week days and 1
weekend), from 00:00 hr on day 1 to 00:00 hr on day 7. The
data were collected over a 1-minute epoch length, and a 6-
day average was calculated.The analysis was performed using
the Actiwatch 7 software (CamNtech Ltd. and Cambridge
Neurotechnology Ltd., Cambridge, UK).TheActiwatch AW7
originates from the Actiwatch AW4, which has similar
reliability to other accelerometers [25] and is an adequate
instrument for assessing daily physical activity [26].
2.4. Measurement of Plasma Irisin and Other Biochemical
Variables. The quantitative measurement of irisin in human
plasma samples was performed using a commercial enzyme-
linked immunosorbent assay (ELISA) kit directed against
amino acids 31–143 of the FNDC5 protein (Irisin ELISA Kit
EK-067-52; Phoenix Pharmaceuticals Inc., CA) according to
the manufacturer’s instructions. The absorbance from each
sample was measured in duplicate using a spectrophotomet-
ric microplate reader at wavelength of 450 nm (Versamax
Microplate Reader; Associates of Cape Cod Incorporated,
East Falmouth, MA).
Insulin was analysed by an immunoradiometric assay
(BioSource International, Camarillo, CA,USA) in a Beckman
Coulter (Fullerton, CA, USA), showing 0.3% cross-reaction
with proinsulin. The intra- and interassay CV were 1.9% and
6.3%, respectively. Glucose was measured using a Dimension
Autoanalyzer (Dade Behrng, Deerfield, IL, USA).The home-
ostatic model assessment index (HOMA-IR) was calculated
following the formula (fasting plasma glucose (mg/mL) ×
fasting plasma insulin (mU/L)/405), as described elsewhere
[27].
2.5. Adipose Tissue Biopsies and FNDC5/Irisin Immunodetec-
tion. The human adipose tissue specimen was obtained with
written informed consent approved for this particular study
by the Comite´ E´tico de Investigacio´n Cl´ınica de Galicia—
CEIC de Galicia (Spain) according to the Declaration of
Helsinki. Adipose tissue was obtained from NW (body
mass index < 35) who underwent cholecystectomy surgery
and OB patients (body mass index > 35) who underwent
laparoscopic gastrectomy surgery.The visceral fat was located
in the hypogastric region around the internal organs, and
the subcutaneous fat was located in the mesogastric region.
The tissues were transported from the operating room to the
laboratory in sterile KRH buffer with penicillin (100U/mL)
and streptomycin (100 𝜇g/mL). Secretome and tissues were
collected and processed for immunodetection as previously
described [5, 16].
2.6. Statistical Analysis. The sample size of the current trial
was estimated by calculating the differences in irisin between
the OB and NW patients according to the equation reported
by Mera et al. [28]. The sample size was established at a
minimum of 26 volunteers per group to detect differences
according to the adiposity levels.
The normal distribution of the variables was tested using
the Kolmogorov-Smirnov and the Shapiro-Wilk tests. The
irisin levels exhibited a nonparametric distribution.However,
based on the sample size of >60 subjects included in the
current study, a one-way ANOVA was used to study the
differences between AN, NW, and OB subjects adjusted by
age. The potential association between anthropometric and
biochemical parameters with and irisin levels was evaluated
using the Pearson coefficient test. Multivariate linear regres-
sion models were fitted to explain the variations in the irisin
plasma levels. Data are reported as the mean ± SE, and
confidence intervals (95% CI) are used to describe the linear
coefficient (B) values.
The statistical analysis was performed using SPSS version
15.0 software (SPSS Inc., Chicago, IL) for Windows XP
(Microsoft, Redmond, WA). 𝑃 ≤ 0.05 was considered to be
statistically significant.
3. Results
As expected, the OB subjects exhibited higher body weight
with higher fat mass and fat-free mass compared with the
AN and NW subjects, with the differences being statistically
significant after adjusting by age (Figure 1(a)). The NW
subjects exhibited statistically higher body weight compared
with theAN subjects accompanied by higher fatmass and fat-
free mass. Considering the body composition as a percentage
of the total body weight, the AN subjects exhibited higher fat-
free mass than the NW and OB subjects (Figure 1(a)).
The differences in the anthropometrical parameters were
consistent with the significantly increased plasma irisin
concentrations in theOB subjects compared with the AN and
NW groups (Figure 1(b)). The NW subjects exhibited a slight
but not statistically significant increase compared with the
AN subjects (𝑃 > 0.05).
Further analysis showed that the irisin levels were posi-
tively correlated with two parameters of adiposity (i.e., body
weight (𝑟 = 0.52; 𝑃 < 0.001) and BMI (𝑟 = 0.52; 𝑃 <
0.001)). The irisin plasma levels were not correlated with
height (𝑟 = −0.05; 𝑃 > 0.05). The correlations indicated that
irisin strongly reflects the body fat mass component, which is
further supported by the bioelectrical impedance analysis of
body composition in which the irisin plasma levels correlated
with the fat mass measured in kg (𝑟 = 0.52; 𝑃 = 0.001;
Figure 2) and the percentage of fat mass (𝑟 = 0.48; 𝑃 <
0.001). However, the muscle component may also contribute
to irisin circulating levels as shown by the positive correlation
between irisin and fat-free mass (𝑟 = 0.43; 𝑃 = 0.001;
Figure 2). An inverse correlation was observed between
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Figure 1: Body composition and plasma irisin circulating levels. Body weight (kg), fat mass (kg), fat-free mass (kg), fat mass (%), and fat-free
mass (%) are shown in the anorexia nervosa, normal weight, and obese groups. (a) Plasma irisin concentration in the three experimental
groups (b).The data are shown as the mean (SE). Statistically significant differences are denoted as (a) 𝑃 < 0.001 versus anorexia nervosa and
(b) 𝑃 < 0.001 versus normal weight and anorexia nervosa.
the irisin levels and the percentage of fat-freemass (𝑟 = −0.53;
𝑃 < 0.001). The associations between irisin and fat mass and
fat-free mass were maintained after adjusting for the studied
groups (data not shown). In addition, a direct association
was observed between plasmatic levels of irisin and glucose
(𝑟 = 0.22; 𝑃 = 0.0026), insulin (𝑟 = 0.34: 𝑃 < 0.001), and
HOMA-IR (𝑟 = 0.33; 𝑃 = 0.001). This positive association
was maintained especially for insulin and HOMA-IR after
adjusting for the studied groups.
Because irisin secretion was shown to be induced by
exercise and energy expenditure [7], the daily physical activ-
ity and resting energy expenditure (REE) were evaluated in
the three BMI groups. The Actiwatch analysis in the OB
subjects exhibited statistically lower daily physical activity
with higher resting energy expenditure (REE) compared with
theNWsubjects adjusted by age (Figures 3(a) and 3(b), resp.).
Therefore, the OB subjects exhibited higher daily physical
activity compared with the extreme AN hospitalized subjects
displaying very limited activity but lower activity compared
with the NW subjects (𝑃 < 0.05). Obesity was accompanied
by increased REE compared with the AN and NW subjects
(𝑃 < 0.05). The plasma irisin levels were inversely correlated
with daily physical activity (𝑟 = −0.22; 𝑃 = 0.001) and
directly correlated with REE (Figures 3(c) and 3(d)). After
adjusting by the BMI group, only the association between
irisin and REE was maintained (𝑟 = 0.34; 𝑃 = 0.001), and
the daily physical activity was not statistically significant (𝑟 =
−0.06; 𝑃 = 0.432).
To further investigate the potential factors involved in
the changes in the irisin plasma levels, a multiple regression
model was performed including REE and physical activity,
adjusting for age, and BMI group (Table 1). The regression
model predicting changes in irisin plasma levels showed
a 21% (𝑃 < 0.001) of the irisin levels variability, mainly
depending on REE, whereas physical activity was not statis-
tically associated. When fat free mass was included in the
regression model, the association between REE and irisin
plasma levels persisted. However, when the same analysis was
Table 1: Independent effects of body composition and activity
markers on variations in irisin plasma levels.
𝐵 (95% CI) 𝑃 value
Model 1∗
REE (Kcal/d) 0.35 (0.01; 0.005) 0.001
Daily physical activity (units/d) −0.14 (−0.17; 0.01) 0.088
Corrected 𝑅2 = 0.21 <0.001
Model 2∗
REE (Kcal/d) 2.15 (0.06; 0.33) 0.006
Daily physical activity (units/d) −0.10 (−0.15; 0.03) 0.202
Fat-free mass (Kg) −1.81 (−9.81; −0.85) 0.020
Corrected 𝑅2 = 0.23 <0.001
Model 3∗
REE (Kcal/d) −0.43 (−0.08; 0.01) 0.060
Daily physical activity (units/d) −0.12 (−0.16; 0.02) 0.139
Fat mass (Kg) 0.94 (0.74; 2.31) <0.001
Corrected 𝑅2 = 0.28 <0.001
Model 4∗
REE (Kcal/d) 0.09 (−0.32; 0.14) 0.435
Daily physical activity (units/d) 0.07 (−10.17; 9.09) 0.119
Fat mass (Kg) 1.7 (0.6; 2.8) 0.003
Fat-free mass (Kg) 1.3 (−4.8; 7.5) 0.657
Corrected 𝑅2 = 0.28 <0.001
∗Adjusted for age and BMI group (0: anorexia nervosa; 1: normal weight; 2:
obesity).
performed including fat mass in the multivariate model, REE
becomes significantly unassociatedwith irisin circulating lev-
els, whereas that fat mass was the main factor and explained
approximately 30% (𝑃 < 0.05) of the irisin concentration
variability independently of age, BMI group, fat-free mass,
daily physical activity, and REE (Table 1). An increase in 1 kg
of fat mass was associated with a 2-fold increase in the irisin
plasma levels (𝑃 = 0.003). These results indicate that REE
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Figure 2: Correlation of circulating irisin with fat mass and fat-free mass. Plasma irisin correlation with fat mass (kg), fat mass (%), fat-free
mass (kg), and fat-free mass (%) for the three groups (NW, AN, and OB) is shown.
influence the irisin circulating levels but in a lesser extent than
fat mass.
In order to assay the participation of adipose tissue
on irisin circulating levels, the immunodetection of this
protein was tested on adipose tissue biopsies from healthy
and obese individuals. As shown in Figure 4, FNDC5/irisin
was detected on visceral and subcutaneous adipose tissue
secretion from NW and OB individuals (Figure 4(a)) and in
OB at both intracellular and secretion level (Figure 4(b)).
4. Discussion
Previous studies are rather controversial, and there is no
general agreement about circulating irisin levels and their
correlation with BMI [14, 15, 17, 18]. The current study per-
formed with patients in conditions of extreme BMI confirms
the positive correlation of circulating irisin and different
parameters of adiposity including body weight, BMI, and fat
mass.This work contributes to novel valuable information by
6 International Journal of Endocrinology
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Figure 4: FNDC5/irisin detection on human adipose tissue. Representative immunoblot detection of FNDC5/irisin in human visceral
adipose tissue (VAT) and subcutaneous adipose tissue (SAT) biopsies from NW and OB subjects (a); FNDC5/irisin immunodetection in
human SAT and VAT biopsies and their secretome from OB individuals (b).
showing that circulating irisin levels correlate positively with
resting energy expenditure and negatively with daily physical
activity. Therefore, the inverse correlation of irisin with daily
physical activity and the direct relationship between irisin
and adiposity indicate that adipose tissue may be a primary
inducer of irisin secretion, especially in obesity.
The recent discovery of the PGC1-𝛼-dependent myokine
FNDC5/irisin, which mediates brown-fat development and
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thermogenesis in white fat, has opened a new field of
research [4, 7, 9–13]. The soluble form of FNDC5 binds to
unidentified receptors on the surface of WAT to induce the
expression of Ucp1 and other BAT-associated genes partly
via increased PPAR-𝛼 expression. As a result, irisin may act
as a muscle-derived energy-expenditure signal that directly
communicates with adipose tissue and induces browning.
This effect may improve the WAT metabolic profile and
enhance whole-body energy expenditure, making irisin a
potential new target for the treatment of metabolic diseases.
The possible beneficial effect of irisin on the treatment
of obesity has been challenged by recent reports showing
unexpected high levels of irisin in obese animals and humans
[14–17] as well as its association with the insulin resistance
onset in association with weight regain [29]. Moreover,
it was observed that in obese individuals, body weight
and BMI reduction by bariatric surgery or by nutritional
intervention significantly reduced irisin circulating levels
[15, 17] and its depletion after an energy restricted program
is associated with the reduction of important lipid [30]
and carbohydrate [31] metabolism biomarkers in patients
with metabolic syndrome. Other reports have described
conflicting data indicating a lack of correlation between the
circulating irisin concentration and the adiposity parameters
[18]. This discrepancy could be due to methodological differ-
ences because there is no consensus concerning the identity
of the soluble portion of the FNDC5 membrane protein,
the mechanism of secretion, or the presence of variations
on target epitopes among manufacturers. However, most
published reports indicate correlations between irisin and
adiposity levels. The present work further corroborates these
findings; irisin plasma levels were elevated in obesity, and
a strong relationship was found between irisin and several
adiposity parameters.
In the current work, the obese subjects exhibited higher
REE compared with the normal weight and anorexia nervosa
subjects and it was directly related to irisin levels, indepen-
dently of daily physical activity. This association between
irisin and energy expenditure was previously reported in a
cohort of postmenopausal women and it was proposed that
this association could be explained by the irisin action on
the brown adipose tissue thermogenesis [32]. However, the
association between irisin and REE appears to be masked by
the strong association between fat mass and irisin plasma
levels. Fat mass was revealed as the main factor explaining
approximately 30%of the variability in the irisin plasma levels
independently of age, fat free mass, daily physical activity,
REE, and BMI group.
The fact that daily physical activity was found to be inde-
pendent of plasma irisin levels in our work may seem con-
trary to what was expected. Bostrom’s results have shown the
expression and secretion of irisin after endurance exercise [7],
which cannot be compared to normal daily activity assayed
in our paper. Moreover, there are studies that, in contrast to
the initial report by Bostrom, have shown no variations of
FNDC5 mRNA expression in muscle or at circulating level
after aerobic or strength exercise training [15, 33, 34]. On
the other hand, an increase of irisin circulating levels was
observed after short-term exercise (sprints) which suggest
that irisin secretion is dependent on acute or chronic sorts of
exercise with a possible counter-regulation/adaptation over
time [35]. Therefore, our results in relation to daily activity
are coherent with previous evidences in the bibliography.
Our group has previously described that FNDC5/irisin is
a myokine and an adipokine expressed and secreted by WAT
[16]. Interestingly, we observed that explants of adipose tissue
from obese animals or humans oversecreted irisin compared
with the control subjects. Therefore, we suggest that the
muscle/adipose secretion ratio may vary and may be affected
by the physiological situation; during exercise, muscle tissue
strongly participates in the FNDC5 circulating levels, while in
atypical BMI cases, such as obesity, the adipose tissue would
actively increase the circulating FNDC5/irisin. The current
work further reinforces this hypothesis, because themain dif-
ference between the obesity and normal weight and anorexia
nervosa subjects is the higher fat mass; therefore, adipose
tissue could be involved in the circulating irisin concentration
differences observed depending on the BMI as reinforced in
preliminary experiments assaying FNDC5/irisin immunode-
tection in adipose tissue from NW and OB individuals in
Figure 4.
The results in the present work with previous reports
[14–17, 36, 37] might suggest a possible mechanism of
resistance to irisin in situations of elevated BMI as previously
observed in other adipokines (e.g., leptin) [38]. The elevated
concentration of circulating irisin in overweight and obese
subjects suggests that a great amount of BAT would be
expected in these patients. Although it is now clear that
BAT is present and functional in adult humans, significant
low amounts of BAT have been described in overweight
and obesity, which supports the irisin-resistance hypothesis
[39, 40]. However, further research should be performed to
confirm this hypothesis.
In conclusion, the current work demonstrates that irisin
circulating levels is associated with energy expenditure inde-
pendently of daily physical activity but in a lesser degree than
fat mass, which was revealed as the main factor influencing
the circulating irisin concentration in obese women with
extreme BMI from anorexia nervosa to obesity. Therefore,
these findings reinforce the positive relationship between
circulating irisin and adiposity and the relevance of WAT-
secreted irisin in situations of elevated BMI, such as obesity.
Further studies are needed to elucidate whether irisin is
involved in obesity development or irisin resistance that exist
in an obesity state to counteract the metabolic disturbances
related to excess adiposity.
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